IGF1R and breast carcinoma: Therefore, novel therapeutic approaches to overcome primary and secondary resistance to trastuzumab include inhibition of angiogenesis and other signaling pathways (PI3K/mTOR, IGF1-R, HSP90) involved in breast cancer growth [5].